Lucid Diagnostics Provides Business Update and Third Quarter 2024 Financial ResultsPRNewsWire • Wednesday
Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed PublicationPRNewsWire • 11/07/24
Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue DriversPRNewsWire • 11/05/24
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024PRNewsWire • 10/30/24
Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA TestPRNewsWire • 10/15/24
American Foregut Society's 2024 Annual Meeting to Highlight Lucid Diagnostics' EsoGuard Esophageal Precancer TestPRNewsWire • 09/24/24
Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World CongressPRNewsWire • 09/10/24
Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile HealthPRNewsWire • 09/03/24
Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard® for Early Detection of Esophageal Precancer and CancerPRNewsWire • 08/20/24
The American Foregut Society Formally Requests Medical Policy Coverage of EsoGuard® to Enhance Early Detection of Esophageal CancerPRNewsWire • 08/13/24
Lucid Diagnostics Provides Business Update and Second Quarter 2024 Financial ResultsPRNewsWire • 08/12/24
Lucid Diagnostics Holds First Major Directly-Contracted EsoGuard® #CheckYourFoodTube Precancer Testing EventPRNewsWire • 08/08/24
Lucid Diagnostics Announces Positive Data from ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer TestingPRNewsWire • 08/06/24
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 12, 2024PRNewsWire • 07/29/24